ticagrelor
Selected indexed studies
- Ticagrelor. (Profiles Drug Subst Excip Relat Methodol, 2022) [PMID:35396017]
- Ticagrelor: clinical development and future potential. (Rev Cardiovasc Med, 2021) [PMID:34258905]
- Ticagrelor: a cardiometabolic drug targeting erythrocyte-mediated purinergic signaling? (Am J Physiol Heart Circ Physiol, 2021) [PMID:33095055]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ticagrelor. (2022) pubmed
- Ticagrelor: clinical development and future potential. (2021) pubmed
- Ticagrelor: a cardiometabolic drug targeting erythrocyte-mediated purinergic signaling? (2021) pubmed
- Ticagrelor-Associated Urticaria. (2023) pubmed
- Is ticagrelor worth its high cost and side-effects? (2019) pubmed
- Ticagrelor resistance: a case series and algorithm for management of non-responders. (2022) pubmed
- Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. (2020) pubmed
- Ticagrelor Use in Stroke Patients: Past, Present, and Future. (2021) pubmed
- Ticagrelor for patients undergoing coronary artery bypass grafting: A meta-analysis of randomized controlled trials. (2023) pubmed
- Does Ticagrelor Improve Endothelial Function? (2019) pubmed